Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProSun: Propranolol + Sunitinib in mRCC
NCT03323710Phase 2Withdrawn
- Sponsor
- Military Institute of Medicine – National Research Institute
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of propranolol in renal cell carcinoma (RCC), sponsored by Military Institute of Medicine – National Research Institute. Planned start Sep 2018; status: withdrawn.
02
Drugs
propranolol
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03323710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323710.